Announcement
Additional Details Required For Corporate Announcement Under Regulation 30(4) Of The SEBI (LODR) Regulations, 2015. 10 Aug - Nureca disclosed CGST rectification settlement via ITC reversal of Rs. 15.40 lakh for FY 2021-22.
Source: Bse
Nureca Limited (NURECA)
Small CapPharma stocks · Small cap · NSE
Nureca Limited operates in Medical Equipment, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
₹328.9
+15.65 · +5.00%
Market cap ₹313.8 Cr
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Official result overlay30 Sept 2026 · nse-xbrl
Latest result21 Oct, 01:55 pm IST
Score22 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags04 Oct 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
77BullishSMA20 +3.1% / mo · MACD − · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 61
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
NURECAD candles · FIT view+23.7%Latest close ₹328.90 on 2026-10-21
Bar
+1.2%
RSI
49
MACD hist
-2.89
52W pos
73%
2026-10-21O ₹324.90H ₹328.90L ₹305.00C ₹328.90Vol 7,463 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
NURECANifty PharmaNifty 500
- NURECA
- +12.6%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- +19.1 pp
Chart stats
21 Oct 2026- From 52W high
- -12.5%
- 52W range position
- 73%
- ATR (14)
- 4.6%
- Volume vs 20D
- 1.07x
- Avg traded value
- ₹0.2 Cr
- 20D price channel
- ₹305 - ₹376
₹376
₹204 - ₹376
₹15.2
Latest completed session
20-session average
35.3% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · OVERVALUED23
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Average52
Revenue +55.1% · PAT +11.6% YoY
Technical
Bullish77
Price trend and sector-relative-strength timing.
Valuation
Legacy model-7142.9%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence64
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Sept 2026
Average · 52/100margin compression · Rev +55% YoY · PAT +12% YoY · +45% QoQ
Filed 21 Oct 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹58.5 Cr | +55.1% | +45.1% |
| EBITDA | ₹5.2 Cr | +59.9% | +52.9% |
| Operating margin | 8.9% | +28 bps | +46 bps |
| PAT | ₹4.1 Cr | +11.6% | +31.9% |
| PAT margin | 6.9% | -270 bps | -69 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 65.93
- P/B
- 1.79
- EV/EBITDA
- 54.33
- Market Cap
- 313.84Cr
Profitability
- ROE
- 1.12%
- ROCE
- 3.30%
- ROA
- 2.04%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- -7.00%
- EPS 5Y
- -46.00%
- Revenue 3Y
- 10.00%
- EPS 3Y
- 30.00%
Balance Sheet
- Debt/Equity
- 0.01
- Interest Coverage
- 4.00×
- Altman Z
- 8.40
- Book Value
- 189.00
Cash Flow
- FCF Yield
- 5.25%
- FCF Positive Y
- 2/5
- OCF
- 3.00 Cr
- EPS TTM
- 4.99
Shareholding
- Promoter Hold
- 68.09%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 79%
Financial History
Updated 22/10/2026
Revenue
₹ CrLatest: 58.5+45.1% vs prev
Net Profit
₹ CrLatest: 4.0+31.9% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bullish setupTrend is constructive — long-term uptrend intact. RSI 49.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 rising (~3.0% over last month) — short-term momentum positive.
- RSI(14) at 49 — rising, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 13% off 52W high · 61% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
83
RS percentile
Stage 2 UptrendEstablished S2
1M return
-2.9%
3M return
+12.6%
6M return
+23.0%
1Y return
+25.5%
RS 1D
+8
RS 20D
-3
Sector rank
#1
Industry rank
#5
Stage evidence
- Price is 15.5% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +3.3%.
- Both 3-month and 6-month returns are positive.
50-DMA
price below
200-DMA
price above
S2 entered
12 Aug 2026
S2 age
48 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 150.27+5.97%
RS vs Nifty 500150
Valuation & peers
U-Score 23 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 23 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation3/30
Growth0/25
Quality0/20
Balance Sheet13/15
Cash Flow5/10
Piotroski
7/9 (+5)
Penalties
-3
Raw sum
23
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
23/100 · legacy band OVERVALUED
Positive drivers
- FCF yield is supportive at 5.3%.
- Piotroski is strong at 7/9.
- Balance sheet contributes 13/15 to the score.
Main drags
- Penalty bucket subtracts 3 points.
- Fair-value margin of safety is negative at -7142.9%.
- Growth is weaker at 0/25; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
65.9
PB
1.8
EV/EBITDA
54.3
ROE
1.1%
ROCE
3.3%
FCF Yield
5.3%
Debt/Equity
0.0
MoS
-7142.9%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 22 Oct 2026
v4.3-runtime-valuation
Final score
23
Previous: 23
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-7142.9%
Previous: -7142.9%
Score history
12 stored score snapshots. Latest stored move: +0 points.
22 Oct 2026
v4.3-runtime-valuation
22
22
22
23
23
22
22
23
23
23
23
23
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹145.67
-125.8% MoS
Growth-justified P/E
0.9
Growth-justified Value
₹4.54
-7142.9% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
INFLUX
SME
Influx Healthtech Ltd.
Medical Devices
match 156
27
31.8
19.0%
-301%
OVERVALUED
VILINBIO
SME
VILIN BIO MED LTD.
Medical Devices
match 130
33
44.6
7.5%
+11%
WATCHLIST
OSELDEVICE
SME
Osel Devices Ltd.
Medical Devices
match 125
60
21.1
18.7%
+55%
UNDERVALUED
GML
SME
Galaxy Medicare Ltd.
Medical Devices
match 125
67
8.3
10.8%
+81%
UNDERVALUED
POLYMED
Large
Poly Medicure Limited
Medical Devices
match 119
32
50.1
9.0%
-5%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Nureca Limited operates in Medical Equipment, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Sept 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
64Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 42nd percentile of the scored universe and 31st percentile within Pharma. Main check: financial discipline is weak at 22/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
31 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
42nd percentile
overall median 67 · Pharma: 31st pctile, median 70 · Small: 47th pctile, median 66
Evidence depth
Financial-only
31 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
90
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
88
strong · leverage and solvency
Discipline
22
weak · capital discipline
Results
29
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 68.1%.
- ▸Promoter pledge is zero.
- ▸Promoter holding increased 3.1%.
- ▸FCF yield is 5.5%.
Trust risks
- ▸3 latest quarters had PAT decline worse than 25% YoY.
- ▸ROCE is low at 3.3%.
- ▸ROE is low at 1.1%.
- ▸ROCE trend is -9%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Nureca Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Investor presentationJul 2026
Jul 2026 · PPT
Source: Bse
AnnouncementJul 2026
Jul 2026 · Announcement under Regulation 30 (LODR)-Change in Management 30 May - Board approved FY26 audited results, Rs100 crore capex, CFO resignation/appointment, and AGM on 28 July 2026.
Source: Bse
Annual reportJul 2026
Jul 2026 · Reg. 34 (1) Annual Report. 2d - Nureca AGM scheduled for July 28, 2026; Annual Report 2025-26 uploaded.
Source: Bse
Annual report
Reg. 34 (1) Annual Report. 8 Jul
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 4 Jul - Nureca Limited has informed regarding newspaper publication.
Source: Bse
Annual report
Nureca Limited Has informed Regarding Notice Of 10Th AGM Of The Company Along With Its Annual Report For The FY25-26. 3 Jul
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Press Release / Media Release 20 Jun - Dr Trust 360 crosses 2.4 million users; launches AI health analytics subscription.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 30 May - Nureca Limited has informed regarding Newspaper Publication.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Change in Management 29 May - Nureca approved FY26 audited results, ₹100 crore capex, CFO resignation/appointment, and director reappointments.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Announcement
Nureca Limited Has informed Regarding The Audited Financial Results For The Quarter And Financial Year Ended 31St March, 2026. 29 May
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.